Your browser is no longer supported. Please, upgrade your browser.
Settings
GERN [NASD]
Geron Corporation
Index- P/E- EPS (ttm)-0.28 Insider Own0.17% Shs Outstand319.16M Perf Week-0.68%
Market Cap481.00M Forward P/E- EPS next Y-0.35 Insider Trans0.00% Shs Float296.50M Perf Month-18.78%
Income-75.60M PEG- EPS next Q-0.08 Inst Own55.80% Short Float9.29% Perf Quarter-13.27%
Sales0.30M P/S1603.33 EPS this Y22.70% Inst Trans2.20% Short Ratio7.14 Perf Half Y-28.29%
Book/sh0.66 P/B2.23 EPS next Y-2.90% ROA-31.00% Target Price- Perf Year25.64%
Cash/sh0.60 P/C2.45 EPS next 5Y5.00% ROE-37.10% 52W Range1.10 - 2.40 Perf YTD-7.55%
Dividend- P/FCF- EPS past 5Y- ROI-32.70% 52W High-41.25% Beta1.13
Dividend %- Quick Ratio6.50 Sales past 5Y-63.00% Gross Margin- 52W Low28.18% ATR0.08
Employees53 Current Ratio6.50 Sales Q/Q-50.00% Oper. Margin- RSI (14)35.59 Volatility5.04% 5.37%
OptionableYes Debt/Eq0.11 EPS Q/Q49.10% Profit Margin- Rel Volume0.44 Prev Close1.47
ShortableYes LT Debt/Eq0.11 EarningsMar 11 AMC Payout- Avg Volume3.86M Price1.41
Recom1.70 SMA20-9.99% SMA50-19.39% SMA200-21.79% Volume1,471,030 Change-4.08%
Feb-18-21Resumed B. Riley Securities Buy $4
Aug-03-20Initiated Stifel Buy $3
Nov-19-19Resumed B. Riley FBR Buy $4
Sep-03-19Initiated H.C. Wainwright Buy $4
Aug-15-19Initiated Cantor Fitzgerald Overweight $4
Apr-09-19Upgrade Needham Hold → Buy $3
Jan-31-19Upgrade B. Riley FBR Neutral → Buy $1.50 → $3.25
Oct-02-18Downgrade B. Riley FBR Buy → Neutral $5.75 → $1.50
Jul-05-18Initiated B. Riley FBR, Inc. Buy $5.75
Sep-13-16Reiterated FBR Capital Outperform $6 → $5
Sep-13-16Reiterated FBR & Co. Outperform $6 → $5
Dec-07-15Reiterated Piper Jaffray Overweight $5 → $10
Apr-21-15Initiated Oppenheimer Outperform $5.50
Jun-12-14Upgrade MLV & Co Hold → Buy $2 → $4.25
Mar-12-14Downgrade MLV & Co Buy → Hold $9 → $2
Dec-10-13Upgrade Needham Hold → Buy $10
Dec-10-13Reiterated MLV & Co Buy $8 → $9
Nov-08-13Reiterated MLV & Co Buy $6.50 → $8
Oct-16-13Initiated MLV & Co Buy $6.50
Aug-30-12Initiated Stifel Nicolaus Buy $4
Apr-19-21 09:30AM  
Apr-18-21 08:00AM  
Apr-14-21 09:40AM  
Apr-13-21 07:30AM  
Mar-18-21 04:45PM  
Mar-12-21 12:06PM  
08:00AM  
03:00AM  
Mar-11-21 04:10PM  
07:00AM  
Mar-10-21 10:08AM  
Mar-04-21 12:30PM  
Mar-01-21 04:45PM  
Feb-18-21 04:45PM  
Feb-07-21 03:54AM  
Jan-21-21 04:45PM  
Jan-14-21 04:45PM  
Dec-17-20 01:25PM  
Dec-11-20 08:30AM  
Dec-10-20 08:30AM  
Dec-07-20 06:45PM  
Nov-19-20 04:30PM  
Nov-10-20 04:30PM  
Nov-08-20 07:51AM  
Nov-06-20 10:31AM  
Nov-05-20 07:20PM  
04:25PM  
04:05PM  
Nov-04-20 04:27PM  
Nov-02-20 11:58AM  
Oct-29-20 04:30PM  
Oct-28-20 04:35PM  
12:32PM  
Oct-23-20 09:03AM  
Oct-01-20 04:30PM  
Sep-21-20 08:53AM  
Sep-17-20 04:30PM  
Sep-09-20 09:00AM  
Aug-24-20 10:52AM  
Aug-20-20 04:30PM  
Aug-06-20 04:05PM  
Aug-04-20 04:45PM  
Jul-30-20 04:30PM  
12:33PM  
Jul-27-20 08:28AM  
08:18AM  
Jul-23-20 11:30AM  
Jul-16-20 08:30AM  
Jul-01-20 08:30AM  
Jun-30-20 08:01AM  
Jun-25-20 10:36AM  
08:38AM  
Jun-24-20 12:35PM  
11:30AM  
Jun-22-20 11:28AM  
Jun-19-20 08:50AM  
Jun-12-20 08:30AM  
Jun-11-20 09:04AM  
Jun-10-20 09:30AM  
Jun-09-20 09:44AM  
08:40AM  
Jun-05-20 11:30AM  
07:29AM  
Jun-02-20 09:08AM  
May-29-20 05:00PM  
May-28-20 06:25PM  
04:05PM  
May-27-20 04:30PM  
May-22-20 11:11AM  
08:13AM  
07:15AM  
May-21-20 04:03PM  
04:01PM  
08:30AM  
May-15-20 01:24PM  
May-14-20 02:22PM  
09:05AM  
Apr-30-20 12:33PM  
Apr-16-20 08:30AM  
Apr-09-20 06:08PM  
Apr-08-20 04:30PM  
08:46AM  
Apr-04-20 09:25AM  
Apr-02-20 08:00AM  
Mar-23-20 02:15PM  
12:30PM  
10:45AM  
10:40AM  
10:14AM  
07:00AM  
02:00AM  
Mar-22-20 12:53PM  
11:05AM  
Mar-21-20 03:50PM  
08:03AM  
Mar-20-20 05:14PM  
01:45PM  
01:05PM  
11:30AM  
10:13AM  
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Farrell Elizabeth G.DirectorAug 21Buy1.7317,44130,17319,641Aug 24 08:57 PM